패밀리 core · Payload core · SMILES 확보
Exploration Score · catalog ranks
Rule-based Catalog Exploration Score for pharmacophore cores and drug/derivative nodes. Not an efficacy prediction.
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.
Core structure exploration tiers
Rule-based Catalog Exploration Score from SMILES similarity, approved/clinical tags, family network size, and SAR metadata. It does not predict efficacy, safety, or development success.
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.
How similarity is calculated · How clustering works · How exploration priority is scored
치료 영역 · 계열
HighHigh exploration priority6
Highest Exploration Score percentile in this pool (X-S bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| High | DM1 DM1 / maytansinoid payload family · Payload | Maytansinoid | 68 | 패밀리 core · Payload core · SMILES 확보 | |
| High | MMAE MMAE (auristatin) payload family · Payload | ADC payload | 66 | 패밀리 core · Payload core · SMILES 확보 | |
| High | SG3199 PBD dimer ADC payload family · Payload | ADC payload | 65 | 패밀리 core · Payload core · SMILES 확보 | |
| High | Duocarmycin SA Duocarmycin CPI ADC payload series · Payload | ADC payload | 63 | 패밀리 core · Payload core · SMILES 확보 | |
| High | Exenatide GLP-1 / incretin agonist series · Drug | GLP-1 / incretin | 59 | 패밀리 core · SMILES 확보 | |
| High | Gefitinib EGFR tyrosine kinase inhibitor series · Drug | EGFR TKI | 59 | 패밀리 core · SMILES 확보 |
패밀리 core · Payload core · SMILES 확보
패밀리 core · Payload core · SMILES 확보
패밀리 core · Payload core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
MedMedium exploration priority10
Upper-mid Exploration Score percentile (X-A bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Med | Diazepam Benzodiazepine GABA-A modulators · Drug | Anxiolytic · GABA | 58 | 패밀리 core · SMILES 확보 | |
| Med | Imatinib BCR-ABL TKI chemical series · Drug | BCR-ABL TKI | 58 | 패밀리 core · SMILES 확보 | |
| Med | Sumatriptan Migraine triptan series · Drug | Migraine · triptan | 58 | 패밀리 core · SMILES 확보 | |
| Med | Levodopa Parkinson dopaminergic / MAO-B series · Drug | Parkinson | 57 | 패밀리 core · SMILES 확보 · 패밀리 9종 | |
| Med | Sotorasib KRAS G12C inhibitor chemical landscape · Drug | KRAS inhibitor | 56 | 패밀리 core · SMILES 확보 | |
| Med | Empagliflozin SGLT2 inhibitor series · Drug | SGLT2 inhibitor | 55 | 패밀리 core · SMILES 확보 | |
| Med | Irinotecan SN-38 / irinotecan (TOP1) small-molecule series · Drug | TOP1 inhibitor | 55 | 패밀리 core · SMILES 확보 | |
| Med | Methylphenidate ADHD stimulant / non-stimulant series · Drug | ADHD | 55 | 패밀리 core · SMILES 확보 | |
| Med | Venetoclax BCL-2 BH3-mimetic inhibitor series · Drug | BCL-2 inhibitor | 55 | 패밀리 core · SMILES 확보 | |
| Med | Exatecan Exatecan / DXd (TOP1 inhibitor) payload family · Drug | TOP1 inhibitor | 54 | 패밀리 core · SMILES 확보 |
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보 · 패밀리 9종
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
MedMedium exploration priority15
Mid-pool Exploration Score (X-B bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Med | Ruxolitinib JAK inhibitor chemical series · Drug | JAK inhibitor | 54 | 패밀리 core · SMILES 확보 | |
| Med | Atorvastatin Statin HMG-CoA reductase inhibitor series · Drug | Statin / HMG-CoA | 53 | 패밀리 core · SMILES 확보 | |
| Med | Fluoxetine SSRI / SNRI antidepressant series · Drug | Antidepressant · SSRI/SNRI | 53 | 패밀리 core · SMILES 확보 | |
| Med | Ibrutinib BTK inhibitor chemical series · Drug | BTK inhibitor | 53 | 패밀리 core · SMILES 확보 | |
| Med | Gabapentin Neuropathic gabapentinoid / SNRI series · Drug | Neuropathic · gabapentinoid | 52 | 패밀리 core · SMILES 확보 | |
| Med | Paclitaxel Taxane diterpenoid series · Drug | Taxane / microtubule | 52 | 패밀리 core · SMILES 확보 | |
| Med | Palbociclib CDK4/6 inhibitor chemical series · Drug | CDK4/6 inhibitor | 52 | 패밀리 core · SMILES 확보 | |
| Med | Selpercatinib RET / MET / NTRK oncogene TKI series · Drug | RET / MET / NTRK TKI | 52 | 패밀리 core · SMILES 확보 | |
| Med | Vemurafenib BRAF / MEK inhibitor chemical series · Drug | BRAF / MEK | 52 | 패밀리 core · SMILES 확보 | |
| Med | Aripiprazole Atypical antipsychotic series · Drug | Antipsychotic | 51 | 패밀리 core · SMILES 확보 | |
| Med | Olaparib PARP inhibitor chemical series · Drug | PARP inhibitor | 51 | 패밀리 core · SMILES 확보 | |
| Med | Zolpidem Sleep / hypnotic series · Drug | Sleep · hypnotic | 51 | 패밀리 core · SMILES 확보 | |
| Med | Alpelisib PI3K / AKT / mTOR inhibitor series · Drug | PI3K / AKT / mTOR | 50 | 패밀리 core · SMILES 확보 | |
| Med | Levetiracetam Antiepileptic drug chemical series · Drug | Antiepileptic · AED | 50 | 패밀리 core · SMILES 확보 | |
| Med | Ubrogepant CGRP gepant migraine series · Drug | Migraine · CGRP gepant | 50 | 패밀리 core · SMILES 확보 |
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
LowLow exploration priority19
Lower Exploration Score — still listed for inspection (X-C bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Low | ARV-110 PROTAC / bifunctional degrader series · Drug | PROTAC / degrader | 49 | 패밀리 core · SMILES 확보 | |
| Low | Crizotinib ALK / ROS1 TKI chemical series · Drug | ALK / ROS1 TKI | 49 | 패밀리 core · SMILES 확보 | |
| Low | Donepezil Cognitive modulator series · Drug | Cognition · dementia | 49 | 패밀리 core · SMILES 확보 | |
| Low | Enlicitide PCSK9 inhibitor chemical & modality series · Drug | PCSK9 / LDL-C | 49 | 패밀리 core · SMILES 확보 | |
| Low | Fingolimod MS S1P modulator series · Drug | MS · S1P | 49 | 패밀리 core · SMILES 확보 | |
| Low | Riluzole ALS neuroprotectant series · Drug | ALS | 49 | 패밀리 core · SMILES 확보 | |
| Low | Daraxonrasib Daraxonrasib · RAS(ON) · Drug | KRAS inhibitor | 48 | 패밀리 core · SMILES 확보 | |
| Low | DXd Exatecan / DXd (TOP1 inhibitor) payload family · Payload | TOP1 inhibitor | 48 | Payload core · SMILES 확보 | |
| Low | MRTX1133 KRAS G12D / RAS(ON) inhibitor series · Drug | KRAS inhibitor | 48 | 패밀리 core · SMILES 확보 | |
| Low | DM4 DM1 / maytansinoid payload family · Payload | Maytansinoid | 46 | Payload core · SMILES 확보 | |
| Low | MMAF MMAE (auristatin) payload family · Payload | ADC payload | 44 | Payload core · SMILES 확보 | |
| Low | Tesirine PBD dimer ADC payload family · Payload | ADC payload | 43 | Payload core · SMILES 확보 | |
| Low | Seco-duocarmycin Duocarmycin CPI ADC payload series · Payload | ADC payload | 41 | Payload core · SMILES 확보 | |
| Low | SMCC-DM1 DM1 / maytansinoid payload family · Linker | Maytansinoid | 40 | Linker hub · SMILES 확보 | |
| Low | CL2A Exatecan / DXd (TOP1 inhibitor) payload family · Linker | TOP1 inhibitor | 38 | Linker hub · SMILES 확보 | |
| Low | GGFG Exatecan / DXd (TOP1 inhibitor) payload family · Linker | TOP1 inhibitor | 38 | Linker hub · SMILES 확보 | |
| Low | SMCC Daraxonrasib · RAS(ON) · Linker | KRAS inhibitor | 38 | Linker hub · SMILES 확보 | |
| Low | Sulfo-SPDB Daraxonrasib · RAS(ON) · Linker | KRAS inhibitor | 38 | Linker hub · SMILES 확보 | |
| Low | Val-Cit MMAE (auristatin) payload family · Linker | ADC payload | 36 | Linker hub · SMILES 확보 |
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
패밀리 core · SMILES 확보
Payload core · SMILES 확보
패밀리 core · SMILES 확보
Payload core · SMILES 확보
Payload core · SMILES 확보
Payload core · SMILES 확보
Payload core · SMILES 확보
Linker hub · SMILES 확보
Linker hub · SMILES 확보
Linker hub · SMILES 확보
Linker hub · SMILES 확보
Linker hub · SMILES 확보
Linker hub · SMILES 확보
Actual weights, formula and input limits
Exploration score method
StructureMoa ranks are a rule-based Exploration Score. An LLM does not predict activity or efficacy. Role, SMILES, and relation signals inside each family are summed and cut into High / Medium / Low exploration priority.
Core tab
- scaffold / payload / linker role weights
- family center-compound bonus
- SMILES source (db · known · pubchem · inherited)
- relation-edge count and derived-child count
Derivative tab
- drug / derivative / adc candidates
- similarity to family center via Morgan fingerprint, radius 2, 2048 bits, Tanimoto
- Approval, clinical and lead tag bonuses have been removed.
Explore tab
- sparse SAR, cross-scaffold pairs, expansion leaves
- weakly linked nodes and catalog-coverage gaps
- relation graph + stored Morgan fingerprints
- category filters
Exploration-priority bins
- High (X-S): top ~12%
- Medium (X-A/X-B): ~12–62%
- Low (X-C): remainder (pools under 5 compounds stay Medium)
Internal exploration metric based on catalog and structural signals. Not a prediction of efficacy, safety, potency, or development success.
평가 시각: 2026. 10. 28. 오후 6:32:15 · 캐시 5분 · 전체 패밀리